Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice

Journal of Immunology

Volumn 157, Issue 1, 1996, Pages 231-238

  Berman, Robert M ^a   Suzuki, Tadamichi ^a   Tahara, Hideaki ^a   Robbins, Paul D ^a   Narula, Satwant K ^b   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; INTERLEUKIN 10; TUMOR MARKER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; ENDOPLASMIC RETICULUM; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGLOBULIN PRODUCTION; KILLER CELL; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRADERMAL; INTERLEUKIN-10; INTERLEUKIN-12; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, INBRED C57BL; MODELS, IMMUNOLOGICAL; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; SPLEEN;

EID: 0029951658     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Boon, T., A. Van Pel, and E. De Plaen. 1989. Tum-transplantation antigens, point mutations, and antigenic peptides: a model for tumor-specific transplantation antigens? Cancer Cells 1:25.
2. Lethe, B., B. van den Eynde, A. van Pel, G. Corradin, and T. Boon. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:2283.
3. Tanaka, K., T. Yoshioka, C. Bieberich, and G. Jay. 1988. Role of major histocompatibility complex class I antigens in tumor growth and metastasis. Annu. Rev. Immun. 6:359.
4. Goodenow, R. S., J. M. Vogel, and R. L. Linsk. 1985. Histocompatibility antigens on murine tumors. Science 230:777.
5. Cromme, F. V., J. Airey, M. T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stern, C. J. Meijer, and J. M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335.
6. Piali, L., A. Fichtel, H.-J. Terpe, B. A. Imhof, and R. H. Gisler. 1995. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181:811.
7. H. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795.
8. + lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421.
9. Kiefer, R., M. L. Supler, K. V. Toyka, and W. J. Streit. 1994. In situ detection of transforming growth factor-beta mRNA in experimental rat glioma and reactive cells. Neurosci. Lett. 166:161.
10. Ruffini, P. A., L. Rivoltini, A. Silvani, A. Boiardi, and G. Parmiani. 1993. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol. Immunother. 36:409.
11. Chen, Q., V. Daniel, D. W. Maher, and P. Hersey. 1994. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56:755.
12. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081.
13. Mosmann, T. R. 1994. Interleukin-10. In The Cytokine Handbook. A. Thomson, ed. Academic Press, London, pp. 223-237.
14. MacNeil, I. A., T. Suda, K. W. Moore, T. R. Mosmann, and A. Zlotnik. 1990. IL-10, a novel growth cofactor for mature and immature T cells. J. Immunol. 145:4167.
15. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1549.
16. Thompson-Snipes, L., V. Dhar, M. W. Bond, T. R. Mosmann, K. W. Moore, and D. M. Rennick. 1991. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J. Exp. Med. 173:507.
17. Rousset, F., E. Garcia, T. Defrance, C. Peronne, N. Vezzio, D. H. Hsu, R. Kastelein, K. W. Moore, and J. Banchereau. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89:1890.
18. Berman, R., T. Suzuki, H. Tahara, P. Robbins, and M. Lotze. 1994. Human and viral interleukin-10 (hIL-10 and vIL-10) mediate opposing effects in tumor immunity, Cytokine 6:571 (Abstr.).
19. Schwarz, M. A., L. D. Hamilton, L. Tardelli, S. K. Narula, and L. M. Sullivan. 1994. Stimulation of cytotoxic activity by interleukin-10. J. Immunother. 16:95.
20. + T lymphocyte migration. J. Immunol. 151:4545.
21. Taga, K., B. Cherney, and G. Tosato. 1993. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int. Immunol. 12:1599.
22. Levi, Y., and C. Brouet. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Invest. 93:424.
23. Moore, K. W., P. Vieira, D. F. Fiorentino, M. L. Troustine, T. A. Khan, and T. R. Mosmann. 1990. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science 248:1230.
24. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Rocarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174: 915.
25. Hsu, D. H., R. de Waal Malefyt, D. F. Fiorentino, M. N. Dang, P. Vieira, J. de Vries, H. Spits, T. R. Mosmann, and K. W. Moore. 1990. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 350:830.
26. Ho, A. S. Y., Y. Liu, T. A. Khan, D.-H. Hsu, J. F. Bazan, and K. W. Moore. 1993. A receptor for interleukin 10 is related to Interferon receptors. Proc. Natl. Acad. Sci. USA 90:11267.
27. Takeuchi, T., R. P. Lowry, and B. Konieczny. 1992. Heart allografts in murine systems. Transplantation 53:1281.
28. Thai, N. L., F. Fu, S. Qian, H. Sun, L. Gao, S. C. Wang, A., Demetris, J. Woo, A. W. Thomson, R. J. Duquesnoy, and J. J. Fung. 1995. Cytokine mRNA profiles in murine orthotopic liver transplantation: graft rejection is associated with augmented Th1 function. Transplantation 59:274.
29. Qin, L., K. D. Chavin, Y. Ding, J. P. Favaro, J. E. Woodward, J. Lin, H. Tahara, P. Robbins, A. Shaked, D. Y. Ho, R. M. Sapolsky, M. T. Lotze, and J. S. Bromberg. 1995. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta or vIL-10. Transplantation 59:809.
30. Qin, L., K. D. Chavin, Y. Ding, H. Tahara, J. Favaro, J. Woodward, T. Suzuki, P. D. Robbins, M. T. Lotze, and J. S. Bromberg. 1996. Retrovirus-mediated transfer of viral interleukin-10 gene prolongs murine cardiac allograft survival. J. Immunol. 156:2316.
31. Holland, G., and A. Zlotnick. 1993. Interleukin-10 and cancer. Cancer Inv. 11: 751.
32. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
33. Donawho, C. K., P. Wolf, and M. L. Kripke. 1994. Enhanced development of murine melanoma in UV-irradiated skin: dose response, waveband dependence, and relation to inflammation. Melanoma Res. 4:93.
34. Blay, J. Y., N. Burdin, F. Rousset, G. Lenoir, P. Biron, T. Philip, J. Banchereau, and M. C. Favrot. 199. Serum interleukin-10 in non Hodgkin's lymphoma: a prognostic factor. Blood 82:2169.
35. Beissert, S., J. Hosoi, S. Grabbe, A. Asahina, and R. D. Granstein. 1995. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol. 154:1280.
36. Richter, G., S. Kruger-Krasagakes, G. Hein, C. Huls, E. Schmitt, T. Diamantstein, and T. Blankenstein. 1993. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53:4134.
37. Suzuki, T., H. Tahara, S. Narula, K. W. Moore, P. D. Robbins, and M. T. Lotze. 1995. Viral interleukin-10 (vIL-10), the human herpes viras-4 cellular IL-10 (cIL-10) homologue, induces local anergy to allogeneic and syngeneic tumors. J. Exp. Med. 182:477.
38. Giovarelli, M., P. Musiani, A. Modesti, P. Dellabonna, G. Casorati, A. Allione, M. Consalvo, F. Cavallo, F. di Pierro, C. De Giovanni, T. Musso, and G. Forni. 1995. The local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody dependent immune memory. J. Immunol. 155: 3112.
39. Allione, A., M. Consalvo, P. Nanni, P. L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M. P. Colombo, P. Dellabonna, H. Hock, T. Blankenstein, F. M. Rosenthal, B. Gansbacher, M. C. Bosco, T. Musso, L. Gusella, and G. Forni. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54:6022.
40. McIntosh, J. K., J. J. Mule, J. A. Krosnick, and S. A. Rosenberg. 1989. Combination cytokine therapy with tumor necross factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Research 49: 1408.
41. Rosenberg, S. A., M. T. Lotze, L. M. Muul, A. E. Chang, F. P. Avis, S. Leitman, W. M. Linehan, C. N. Robertson, R. E. Lee, J. T. Rubin, C. A. Seipp, C. G. Simpson, and D. E. White. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316:889.
42. Lotze, M. T., J. T. Rubin, S. Carty, H. Edington, T. Carlos, J. Kirkwood, B. Lembersky, T. Logan, M. Rosenstein, M. E. Rybak, T. Whiteside, E. Elder, R. C. Moen, W. Jacob, Y. Chen, R. L. Pinkus, and J. Bryant. 1994. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5:41.
43. Oldham, R. K., G. Blumenschein, L. Schwartzberg, R. Birch, and J. Arnold. 1992. Combination therapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol. Biother. 4:4.
44. Donohue, J. H., M. Rosenstein, A. E. Chang, M. T. Lotze, R. J. Robb, and S. A. Rosenberg. 1984. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocyte lines to cure a disseminated syngeneic lymphoma. J. Immunol. 132:2123.
45. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J. Immunol. 153:1697.
46. Asher, A. L., J. J. Mule, A. Kasid, N. P. Restifo, J. C. Salo, C. M. Reichert, G. Jaffe, B. Fendly, M. Kriegler, and S. A. Rosenberg. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227.
47. Ho, A. S.-Y., and K. W. Moore. 1994. Interleukin-10 and its receptor. Ther. Immunol. 1:173.
48. Trinchieri, G., M. Rengaraju, A. D'Andrea, and N. M. Valiante. 1993. Producer cells of interleukin-12. Immunol. Today 14:237.
49. Mueller, G., J. Saloga, T. Germann, I. Bellinghausen, M. Mohamadzadeh, T. Knop, and A. H. Enk. 1994. Identification and induction of human keratinocyte-derived IL-12. J. Clin. Immunol. 94:1799.
50. Scott, P. 1993. IL-12: initiation cytokine for cell-mediated immunity. Science 260:496.
51. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
52. Murphy, E. E., G. Terres, S. E. Macatonia, C. S. Hsieh, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, and A. O'Garra. 1994. B7 and IL-12 cooperate for proliferation and IFN-γ production by mouse Th clones that are unresponsive to B7 costimulation. J. Exp. Med. 180:223.
53. Kubin, M., M. Kamoun, and G. Trinchieri. 1994. IL-12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180:211.
54. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Louden, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
55. Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869.
56. Chan, S. H., M. Kobayashi, D. Santoli, B. Perussia, and G. Trinchieri. 1992. Mechanism of IFN-γ induction by natural killer cell stimulatory factor (NKSF/ IL-12). J. Immunol 148:92.
57. Germann, T., A. Partenheimer, and E. Rude. 1990. Requirements for the growth of Th1 lymphocyte clones. Eur. J. Immunol. 20:2035.
58. Tan, J. C., S. R. Indelicato, S. K. Narula, P. J. Zavodny, and C. C. Chou. 1993. Characterization of interleukin-10 receptors on human and mouse cells. J. Biol. Chem. 268:21053.
59. Tahara, H., G. M. Mueller, C. Ricordi, P. D. Robbins, and M. T. Lotze. 1992. Islet cell transplantation facilitated by gene transfer. Transplant. Proc. 24:2975.
60. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
61. Danos, O., and R. C. Mulligan. 1988. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85:6460.
62. Chernoff, A. E., E. V. Granowitz, L. Shapiro, E. Vannier, G. Lonnemann, J. B. Angel, J. S. Kennedy, A. R. Rabson, S. M. Wolff, and C. A. Dinarello. 1995. A randomized, controlled trial of IL-10 in humans. J. Immunol. 154:5492.
63. 1 mice. J. Exp. Med. 179:305.
64. Wogensen, L., X. Huang, and N. Sarvetnick. 1993. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J. Exp. Med. 178:175.
65. Wogensen, L., M.-S. Lee, and N. Sarvetnick. 1994. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J. Exp. Med. 179:1379.